{
  "ZYXI": {
    "fullname": "Zynex, Inc. ",
    "number": 32.01,
    "bought": "YES",
    "value_bought": 500.0,
    "value_current": 501.28,
    "value_sold": "-",
    "virtual_result": 1.28,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:36:53",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:48:50",
    "timestamp_data": "2020/08-26 15:48:30",
    "description": "Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.00302546,
    "surface_factor": 2.3609524
  },
  "ZYNE": {
    "fullname": "Zynerba Pharmaceuticals, Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:31:25",
    "timestamp_data": "-",
    "description": "Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.00023045,
    "surface_factor": 3.3569697
  },
  "ZYME": {
    "fullname": "Zymeworks Inc. ",
    "number": 16.03,
    "bought": "YES",
    "value_bought": 500.14,
    "value_current": 500.94,
    "value_sold": "-",
    "virtual_result": 0.8,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:32:48",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:48:53",
    "timestamp_data": "2020/08-26 15:48:35",
    "description": "Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and collaboration with Applied BioMath, LLC. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",
    "exchange": "NYSE",
    "derivative_factor": 0.00638856,
    "surface_factor": 1.73801444
  },
  "ZVO": {
    "fullname": "Zovio Inc. ",
    "number": 109.41,
    "bought": "YES",
    "value_bought": 500.0,
    "value_current": 495.63,
    "value_sold": "-",
    "virtual_result": -4.37,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:32:50",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:48:54",
    "timestamp_data": "2020/08-26 15:48:40",
    "description": "Zovio Inc operates as an education technology services company in the United States. The company's academic institutions, Ashford University offer associate's, bachelor's, master's, and doctoral degree programs in the disciplines of business, education, psychology, social sciences, and health sciences. It also operates a Web development school; and offers an online education platform that provides tutoring and online courses. The company offers its programs primarily through online; and at its campuses. As of December 31, 2019, its institutions offered approximately 1,210 courses and 90 degree programs; and had 34,722 students enrolled. The company was formerly known as Bridgepoint Education, Inc. and changed its name to Zovio Inc in April 2019. Zovio Inc was founded in 1999 and is headquartered in Chandler, Arizona.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.00153365,
    "surface_factor": 3.32754208
  },
  "ZUO": {
    "fullname": "Zuora, Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:31:45",
    "timestamp_data": "-",
    "description": "Zuora, Inc. provides cloud-based software on a subscription basis that enables companies in various industries to launch, manage, and transform into a subscription business. The company offers Zuora Central platform that acts as an intelligent subscription management hub that allows customers to orient order-to-revenue operations. Its products include Zuora Billing for subscription billing; Zuora RevPro, a revenue recognition automation solution; Zuora CPQ for configuring deals, pricing, and quoting in a subscription business; and Zuora Collect designed to handle the complicated function of collections associated with subscription-based businesses. The company also provides Zuora Marketplace that offers industry-specific tools and third-party applications for its customers. Zuora, Inc. sells its products through its direct sales force, global systems integrators, management consulting firms, resellers, technology and ecosystem partners. The company was incorporated in 2006 and is headquartered in Redwood City, California.",
    "exchange": "NYSE",
    "derivative_factor": 0.00258628,
    "surface_factor": 4.8239526
  },
  "ZUMZ": {
    "fullname": "Zumiez Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:31:49",
    "timestamp_data": "-",
    "description": "Zumiez Inc., together with its subsidiaries, operates as a specialty retailer of apparel, footwear, accessories, and hardgoods for young men and women. Its hardgoods include skateboards, snowboards, bindings, components, and other equipment. As of February 29, 2020, the company operated 718 stores, including 607 stores in the United States, 52 stores in Canada, 48 stores in Europe, and 11 stores in Australia under the names of Zumiez, Blue Tomato, and Fast Times. It also operates zumiez.com, blue-tomato.com, and fasttimes.com.au e-commerce websites. Zumiez Inc. was founded in 1978 and is headquartered in Lynnwood, Washington.",
    "exchange": "NASDAQ",
    "derivative_factor": 0.00979053,
    "surface_factor": 0.95499301
  },
  "ZTS": {
    "fullname": "Zoetis Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:31:52",
    "timestamp_data": "-",
    "description": "Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.",
    "exchange": "NYSE",
    "derivative_factor": -0.00224831,
    "surface_factor": 0.3239538
  },
  "ZTO": {
    "fullname": "ZTO Express (Cayman) Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:31:57",
    "timestamp_data": "-",
    "description": "ZTO Express (Cayman) Inc. provides express delivery and other value-added logistics services in the People's Republic of China. The company offers delivery services for e-commerce and traditional merchants, and other express service users. As of December 31, 2019, it operated a fleet of approximately 6,450 self-owned trucks. The company was founded in 2002 and is headquartered in Shanghai, the People's Republic of China.",
    "exchange": "NYSE",
    "derivative_factor": 0.00258792,
    "surface_factor": 0.5600864
  },
  "ZSAN": {
    "fullname": "Zosano Pharma Corporation ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:32:03",
    "timestamp_data": "-",
    "description": "Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.00025586,
    "surface_factor": 5.36187447
  },
  "ZOM": {
    "fullname": "Zomedica Pharmaceuticals Corp. ",
    "number": 4166.67,
    "bought": "YES",
    "value_bought": 500.0,
    "value_current": 500.0,
    "value_sold": "-",
    "virtual_result": 0.0,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:32:56",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:49:04",
    "timestamp_data": "2020/08-26 15:49:00",
    "description": "Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.",
    "exchange": "NYSE",
    "derivative_factor": -2.094e-05,
    "surface_factor": 6.29593778
  },
  "ZNGA": {
    "fullname": "Zynga Inc. ",
    "number": 54.95,
    "bought": "YES",
    "value_bought": 500.05,
    "value_current": 502.24,
    "value_sold": "-",
    "virtual_result": 2.19,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:32:57",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:49:05",
    "timestamp_data": "2020/08-26 15:49:04",
    "description": "Zynga Inc. develops, markets, and operates social games as live services in the United States and internationally. The company's games are played on mobile platforms, such as Apple iOS and Google's Android operating systems, as well as on social networking sites, such as Facebook and Snapchat. It also provides advertising services comprising mobile advertisements, engagement advertisements and offers, and branded virtual items and sponsorships to advertising networks, agencies, and brokers; and licenses its own brands. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.0006143,
    "surface_factor": 1.15135582
  },
  "ZIXI": {
    "fullname": "Zix Corporation ",
    "number": 82.1,
    "bought": "YES",
    "value_bought": 499.99,
    "value_current": 501.63,
    "value_sold": "-",
    "virtual_result": 1.64,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:32:59",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:49:07",
    "timestamp_data": "2020/08-26 15:47:52",
    "description": "Zix Corporation provides email encryption, data loss prevention (DLP), threat protection, and archiving for the secure exchange of email in the United States. The company offers Advanced Email Threat Protection, a cloud-based service that defends organizations from zero-day malware, ransomware, phishing, CEO fraud, W-2 phishing attacks, spams, and viruses in email; Information Archive, a cloud-based email retention solution that enables user retrieval, compliance, and e-discovery; Email Encryption Service that allows a user to send encrypted email to any email user anywhere and on any Internet-enabled device; cloud-based cybersecurity solutions; and e-signatures and secure file sharing solutions. It serves the healthcare, financial services, insurance, and government sectors. Zix Corporation sells its services through a direct sales force; and a network of resellers and other distribution partners. The company was formerly known as ZixIt Corporation and changed its name to Zix Corporation in 2002. Zix Corporation was incorporated in 1988 and is headquartered in Dallas, Texas.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.00075688,
    "surface_factor": 0.94011505
  },
  "ZIOP": {
    "fullname": "ZIOPHARM Oncology Inc ",
    "number": 181.16,
    "bought": "YES",
    "value_bought": 500.0,
    "value_current": 496.38,
    "value_sold": "-",
    "virtual_result": -3.62,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:33:00",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:49:08",
    "timestamp_data": "2020/08-26 15:48:53",
    "description": "ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.0005297,
    "surface_factor": 2.16879891
  },
  "ZION": {
    "fullname": "Zions Bancorporation N.A. ",
    "number": 15.39,
    "bought": "YES",
    "value_bought": 500.02,
    "value_current": 498.17,
    "value_sold": "-",
    "virtual_result": -1.85,
    "final_result": "-",
    "timestamp_bought": "2020-08-26 21:33:01",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:49:10",
    "timestamp_data": "2020/08-26 15:49:05",
    "description": "Zions Bancorporation, National Association provides various banking and related services primarily in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company offers community banking services, such as small and medium-sized business and corporate banking; commercial and residential development, construction, and term lending; retail banking; treasury cash management and related products and services; residential mortgage servicing and lending services; trust and wealth management services; capital markets services, including municipal finance advisory and underwriting; and investment services. It also offers personal banking services to individuals, including home mortgages, bankcards, other installment loans, home equity lines of credit, checking accounts, savings accounts, certificates of deposit of various types and maturities, trust services, safe deposit facilities, and internet and mobile banking services. In addition, the company provides self-directed brokerage services; small business administration lending and secondary market agricultural real estate mortgage loans; corporate trust services for municipalities; and bond transfer, stock transfer, and escrow services. As of December 31, 2019, it operated 434 branches. The company was formerly known as ZB, National Association and changed its name to Zions Bancorporation, National Association in September 2018. Zions Bancorporation, National Association was founded in 1873 and is headquartered in Salt Lake City, Utah.",
    "exchange": "NASDAQ",
    "derivative_factor": 0.00297341,
    "surface_factor": 1.059059
  },
  "ZI": {
    "fullname": "ZoomInfo Technologies Inc. ",
    "number": "-",
    "bought": "NO",
    "value_bought": "-",
    "value_current": "-",
    "value_sold": "-",
    "virtual_result": "-",
    "final_result": "-",
    "timestamp_bought": "-",
    "timestamp_sold": "-",
    "market_state": "CLOSED",
    "timestamp_updated": "2020-08-26 21:32:45",
    "timestamp_data": "-",
    "description": "ZoomInfo Technologies Inc. operates cloud-based go-to-market intelligence platform for sales and marketing teams in the United States and internationally. The company's platform helps sales and marketing professionals to identify the target customers, pinpoint the right decision makers, obtain continually updated predictive lead and company scoring, monitor buying signals and other attributes of target companies, craft the right message, engage via automated sales tools, and track progress through the deal cycle. Its customers operate in various industry verticals, including software, business services, manufacturing, telecommunications, financial services and insurance, retail, media and internet, transportation, education, hospitality, healthcare, and real estate, as well as global enterprises, mid-market companies, and small and medium-sized business. The company was founded in 2007 and is headquartered in Vancouver, Washington.",
    "exchange": "NASDAQ",
    "derivative_factor": -0.0015674,
    "surface_factor": 4.01866904
  }
}